Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified Autologous Leukocyte Cells for AKI After Cardiac Surgery
NCT07052513Phase 2Suspended
- Sponsor
- M2RLAB
- Start
- Dec 2025
- Primary completion
- Jun 2028
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of M2RLAB 001 in acute kidney injury (AKI) (2 arms), sponsored by M2RLAB. Primary endpoints: Recovery time of kidney function, Proportion of participants with persistently altered creatinine values at Day 7 and 4 more. Started Dec 2025; status: suspended.
02
Drugs
M2RLAB 001
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT07052513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052513.